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Aims Biomarkers can be used for diagnosis, risk stratification, or management of patients with heart failure (HF). Knowledge
about the biological variation is needed for proper interpretation of serial measurements. Therefore, we aimed to
determine and compare the biological variation of a large panel of biomarkers in healthy subjects and in patients with
chronic HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
The biological variability of established biomarkers [NT-proBNP and high-sensitivity troponin T (hsTnT)], novel
biomarkers [galectin-3, suppression of tumorigenicity 2 (ST2), and growth differentiation factor 15 (GDF-15)], and
renal/neurohormonal biomarkers (aldosterone, phosphate, parathyroid hormone, plasma renin concentration, and
creatinine) was determined in 28 healthy subjects and 83 HF patients, over a period of 4 months and 6 weeks,
respectively. The analytical (CVa), intraindividual (CVi), and interindividual (CVg) variations were calculated, as well
as the reference change value (RCV), which reflects the percentage of change that may indicate a ‘relevant’ change.
All crude biomarker levels were significantly increased or decreased in HF patients compared with controls (all P
< 0.01). Variation indices were comparable in healthy individuals and HF patients. CVi was not influenced by the
individual levels of the biomarker itself. NT-proBNP and GDF-15 had relatively high CVi (21.8% and 16.6%) and RCV
(61.7% and 64.3%), whereas ST2 (CVi, 15.0; RCV, 42.9%), hsTnT (CVi, 11.1; RCV, 31.4%), and galectin-3 (CVi, 8.1;
RCV, 25.0%) had lower indices of variation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Biological variation indices are comparable between healthy subjects and HF patients for a broad spectrum of
biomarkers. NT-proBNP and GDF-15 have substantial variation, with lower variation for ST2, hsTnT, and galectin-3.
These data are instrumental in proper interpretation of biomarker levels in HF patients.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Biomarkers are helpful for diagnosis, risk stratification, and man-
agement of patients. Incorporation of biomarkers in heart failure
(HF) management is therefore recommended by the European and
American guidelines, with different levels of evidence for various
biomarkers.1,2
For prognostic purposes, serial measures have been shown to
provide superior power over a single measurement.3–7 Also, for
disease monitoring, serial test results proved to be specifically
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.. useful.8,9 Ideally, changes over time should reflect clinical improve-
ment or disease progression. However, proper interpretation as to
whether these changes over time are clinically relevant is complex.
There are two factors that influence the variability of a biomarker:
(i) the analytical variability (imprecision of the test); and (ii) the bio-
logical variability (expected variability within a subject over time).10
Although the concept of biological variation has been established
in the 1980s,11 it is still evolving.12 One of the key parameters is the
so-called reference change value (RCV), which is the percentage
change in a biomarker within an individual that is necessary to
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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reflect a ‘true’ change. This technique was recently employed to
define the significance of changes in high-sensitivity troponin values
in dialysis patients and manifested potent prognostic efficacy.13
However, studies on biological variation are relatively scarce,
and most have been conducted in healthy subjects.14–16 Addi-
tionally, it remains questionable if biological variation in healthy
subjects is identical to biological variation in disease patients. To
date, few studies have therefore reported on biological variation
in patients with HF.17,18
It is currently unknown whether the variation in a diseased pop-
ulation is comparable, and for several old and new HF biomarkers,
including aldosterone, renin, suppression of tumorigenicity 2 (ST2),
and growth differentiation factor 15 (GDF-15), biological variation
is unknown.
Therefore, our aim was to assess the conjoint analytical and bio-
logical variation of the established clinical biomarkers NT-proBNP
and high-sensitivity troponin T (hsTnT), the novel biomarkers,
galectin-3, ST2, and GDF-15, the renal/neurohormonal biomark-
ers including creatinine, aldosterone, plasma renin concentration
(PRC), phosphate, and parathyroid hormone (PTH), and the tightly
regulated electrolyte calcium, in healthy subjects and in chronic
HF patients. We determined which increases/decreases over time
would be of clinical relevance and whether these results differ
between healthy subjects and chronic HF patients.
Methods
Healthy subjects
The healthy subjects were enrolled locally at the University Medical
Center Groningen (UMCG). They had no medical history of cardiac
disease and reported to be healthy. Nobody received medication and
all had normal estimated glomerular filtration rate (eGFR) and normal
values of NT-proBNP. We aimed to include 50% female subjects. A
total of 30 subjects were included in this study to assess biological
variation. Blood was drawn at five different time points each 4 weeks
apart. A complete biomarker set was available in 28 subjects who were
included in our analyses. This study was approved by the local Medical
Ethics Committee (METC 2011.296).
Chronic heart failure patients
The HF patient cohort has been described in detail previously (Clinical
trial identifier NCT01092130).19,20 In brief, 101 HF patients ≥18 years
of age with an LVEF <45% were included, who received optimal HF
medication [i.e. ACE inhibitor or ARB), beta-blocker, and mineralocor-
ticoid receptor antagonist (MRA), when indicated]. In our substudy, all
biomarker measurements were available at three time points (3weeks
apart) for 83 subjects.
Both studies and the current analyses have been performed con-
forming to the Declaration of Helsinki, and all study subjects provided
written informed consent.
Biomarker assays
The markers NT-proBNP, hsTnT, PTH, calcium, phosphate, and cre-
atinine were measured using the Roche Modular system (Roche,
Mannheim, Germany). Galectin-3 was measured with the BG medicine ..
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.. enzyme-linked immunosorbent assay (Waltham, MA, USA). Plasma ST2
was measured with the Presage® ST2 Assay (Critical Diagnostics, San
Diego, CA, USA). The GDF-15 concentrations were determined by a
quantitative sandwich enzyme immunoassay technique (Quantikine®;
R&D Systems, Inc., Minneapolis, MN, USA). The PRC was measured
using a radioimmunometric assay kit for the quantitative determina-
tion of active renin (Cisbio International, Codolet, France). Plasma
aldosterone was measured using a solid phase 125I radioimmunoassay
(Siemens Diagnostics, The Netherlands). The same assays were used
in both cohorts, and all samples of the same subjects over time were
measured at the same time within the same plate.
Mathematical calculations for all
biological variation-associated
parameters
Normally distributed, continuous data are expressed as mean values
(±SD). In comparisons between groups, differences between mean
values of continuous data were calculated using the two-sample t-test.
Non-normally distributed continuous data are expressed as median
values [interquartile range (IQR)], and differences were calculated
using the Mann–Whitney U-test. Differences in categorical values were
calculated using Pearson’s 𝜒2 test. We assessed the biological variation
by the method of Fraser and Harris.10 The coefficient of variation (CV)
is defined as the ratio of the standard deviation (𝜎) to the mean (𝜇):
CV = 𝜎∕μ × 100%
The CV can be assessed for the differences between sample mea-
surements [analytical variability (CVa)] or between subjects in the same
cohort (CVg). The within-individual biological CV (CVi) was calculated
from the median CV between different time points of an individual
(CVt) adjusted for the analytical imprecision (CVa):
CVi =
(
CV2t –Cv
2
a
)1∕2
The index of individuality (II), which can determine whether refer-
ence ranges or monitoring is appropriate, is calculated as follows:
(
CV2a + CV
2
i
)1∕2∕CVg
The II has been used by many to investigate the utility of conven-
tional population-based reference values. For a high II (>1.4), it has
been reported that reference intervals will be more useful than for a
low index (<0.6).21
The symmetrical limits of the normal RCV were calculated as
follows:
RCV = Z × 21∕2 ×
(
CV2a + CV
2
i
)1∕2
The Z score=1.96 which corresponds to a 95% confidence level.
With the log-normal approach, the median normal deviation of the
log-normal distribution (𝜎 ln) was calculated from the median CVt (as a
decimal value), as described by Fokkema et al.:22
𝜎ln =
[
ln
(
CV2t + 1
)]1∕2
The asymmetrical limits for the upward (positive) value for the
log-normal RCV (RCVpos) and for the downward (negative) value for
the log-normal RCV (RCVneg), were determined as:
RCVpos =
[
exp
(
1.96 × 21∕2 × 𝜎ln
)
– 1
]
× 100
RCVneg =
[
exp
(
–1.96 × 21∕2 × 𝜎ln
)
– 1
]
× 100
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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We performed linear regression analyses to determine whether an
association exists between the biomarker value and the variation within
an individual.
For all analyses, P-values <0.05 were considered to denote sig-
nificant differences. Analyses were performed with Microsoft Excel
2007 and STATA software (version 13.0; Stata Corp, College Station,
TX, USA).
Results
Baseline characteristics
Data from 28 healthy subjects were available for the current analy-
ses. The mean (±SD) age was 43 (±13) years, and 14 (50%) subjects
were female. Regarding chronic HF patients, 83 subjects had a com-
plete biomarker set and were therefore eligible for this substudy.
Most of the patients (92%) were classified as NYHA class II. A full
description of the exclusion criteria for the HF cohort is presented
on the last page of the Supplementary material online. These cri-
teria were designed in order to enrol stable HF patients. To cor-
roborate further the stability of our HF cohort, we repeated our
analyses in those patients without an event (HF rehospitalization
or all-cause mortality) in ∼5 years (Supplementary material online,
Table S1). Indeed, no differences were observed between patients
with or without an event, supporting the (very) stable situation
of the patients. The patients enrolled in this study were random-
ized to receive 2000 U of 25-hydroxyvitamin D or no treatment.
We observed no differences for CVi and/or RCV between the two
study groups (data not shown). Chronic HF patients differed sub-
stantially from healthy controls with respect to cardiovascular risk
factors such as smoking and diabetes, the use of medication, and
biochemical variables. The mean (±SD) age was 64 (±10) years,
and 4 (5%) subjects were female. Median (IQR) NT-proBNP was
377 (223–777) pg/mL. The baseline characteristics of both cohorts
are reported in Table 1.
Biological variation
All biomarker levels were significantly different between groups
(Table 2). Nearly all biomarkers (except for GDF-15) exhibited a
CVa <5%. Although HF patients were stable, the CVg was larger
for nearly all biomarkers compared with healthy controls. Only
galectin-3 and calcium showed comparable variation within the
group (data not shown). To investigate further the biological vari-
ation, we calculated the CVi for both cohorts and observed no
significant differences except for aldosterone, phosphate sodium,
and PTH (Table 3). Comparing the CVi between all the biomarkers,
creatinine had the lowest variation, which was comparable with the
tightly regulated electrolytes calcium sodium. Regarding the cardiac
markers, galectin-3 and hsTnT demonstrated the lowest CVi. In
healthy individuals, it can clearly be observed that the II was >0.6
for all the renal/neurohormonal markers except for creatinine and
PTH, which implicates that population-derived references can be
applied.21 This is not the case for cardiac markers in both cohorts,
all showing II <0.6. So, the patient-specific set point is more impor-
tant regarding interpretation than the references based upon the
population. We calculated the RCV to determine the percentage ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Table 1 Baseline characteristics of the healthy
subjects and the chronic heart failure patients
Characteristics Controls
(n= 28)
CHF
(n= 83)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years), mean (SD) 43 (13) 64 (10)
Male, n (%) 14 (50) 79 (95)
SBP (mm Hg), mean (SD) 130 (22) 116 (17)
DBP (mm Hg), mean (SD) 81 (17) 71 (11)
Heart rate, mean (SD) 72 (12) 68 (10)
BMI (kg/m2), mean (SD) 24 (4) 28 (4)
Hypertension, n (%) – 28 (34)
Hypercholesterolaemia, n (%) – 45 (54)
Diabetes, n (%) – 12 (14)
Current smoker, n (%) 0 (0) 19 (23)
HF history
Ischaemic aetiology – 60 (72)
NYHA II, n (%) – 76 (92)
NYHA III, n (%) – 7 (8)
LVEF (%), mean (SD) – 35 (8)
Treatment
Loop diuretic, n (%) 0 (0) 42 (51)
ACE inhibitor/ARB, n (%) 0 (0) 83 (100)
Beta-blocker, n (%) 0 (0) 81 (98)
MRA, n (%) 0 (0) 23 (28)
Laboratory measurements
Creatinine (μmol/L), median (IQR) 74 (67–83) 89 (80–98)
NT-proBNP (pg/mL), median (IQR) 39 (18–57) 377 (223–777)
BMI, body mass index; CHF, chronic heart failure; DBP, diastolic blood pressure;
HF, heart failure; IQR, interquartile range; MRA, mineralocorticoid receptor
antagonist; SBP, systolic blood pressure.
change in serial measurements that would probably repress a true
(statistically significant) rise or fall. Comparably with CVi, no dif-
ferences in RCV of the biomarkers were observed between HF
patients and controls except for aldosterone, phosphate, sodium
and PTH. A complete overview of all the biological variation indices
is presented in Table 4 (healthy subjects) and Table 5 (HF patients).
In addition, besides the CVi, the RCV is also directly compared
between healthy controls and HF patients in Table 3.
Biomarker variation over the biomarker
spectrum
We assessed whether the degree of variation would be associ-
ated with the circulating levels of a given biomarker. Therefore, we
performed linear regression analyses, relating the actual baseline
biomarker levels to the variation. We observed no clear associa-
tion(s) between the CVi and the level of the biomarker, as displayed
in Figure 1 and in Figure S1 of the Suppplementary material online,
except for phosphate and sodium.
Sample regimen
Timing and frequency of sampling are important factors to be
considered when obtaining reliable CVi and RCV. To explore
this, we performed a sensitivity analysis with another sampling
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 All biomarker levels compared between healthy subjects and chronic heart failure patients
Controls (n= 28) CHF (n= 83) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Established biomarkers
NT-proBNP, ng/L 39 (18–57) 377 (223–777) <0.001
hsTnT, pg/mL 3.2 (3.0–4.2) 5.8 (3.0–12.9) 0.001
Novel biomarkers
Galectin-3, ng/mL 10.7 (9.3–12.5) 16.1 (14.4–18.8) <0.001
GDF-15, ng/L 356 (292–533) 923 (687–1441) <0.001
ST2, ng/mL 22.0 (19.6–27.4) 27.5 (21.9–33.6) 0.003
Renal/neurohormonal biomarkers
Creatinine, μmol/L 74 (67–83) 89 (80–98) <0.001
Plasma renin concentration, ng/L 17 (13–22) 74 (18–200) <0.001
Aldosterone, nmol/L 0.22 (0.18–0.30) 0.25 (0.14–0.40) 0.028
Phosphate, mmol/L 1.2 (1.1–1.3) 1.0 (0.9–1.0) <0.001
PTH, pmol/L 4.7 (3.2–6.2) 6.5 (5.0–9.3) <0.001
Electrolytes
Calcium, mmol/L 2.4 (2.4–2.4) 2.3 (2.2–2.3) <0.001
Sodium, mmol/L 145 (143–147) 141 (140–142) <0.001
Values are median (interquartile range).
CHF, chronic heart failure; GDF-15, growth differentiation factor 15; hsTnT, high-sensitivity troponin T; PTH, parathyroid hormone; ST2, suppression of tumorigenicity 2.
Table 3 The within-individual coefficient of variation and the reference change value compared between healthy
controls and chronic heart failure patients
Within-individual
coefficent of variation
Reference change value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Controls CHF P-value Controls CHF P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Established biomarkers
NT-proBNP 25.1 21.8 0.36 70.7 61.7 0.37
hsTnT 16.0 11.1 0.13 44.9 31.4 0.13
Novel biomarkers
Galectin-3 8.1 8.1 0.97 24.6 25.0 0.92
GDF-15 18.9 16.6 0.40 69.9 64.3 0.44
ST2 10.5 15.0 0.09 31.9 42.9 0.13
Renal/neurohormonal biomarkers
Creatinine 4.1 5.0 0.20 12.4 15.0 0.18
Plasma renin concentration 30.1 32.6 0.62 83.8 90.8 0.61
Aldosterone 36.6 27.7 0.033 104.2 80.2 0.031
Phosphate 6.9 10.7 0.021 19.8 30.0 0.024
PTH 16.7 22.5 0.019 46.3 62.4 0.019
Electrolytes
Calcium 1.7 1.6 0.45 6.6 6.3 0.53
Sodium 1.9 0.8 <0.01 5.9 3.1 <0.01
CHF, chronic heart failure; GDF-15, growth differentiation factor 15; hsTnT, high-sensitivity troponin T; PTH, parathyroid hormone; ST2, suppression of tumorigenicity 2.
regimen, comparing CVi and RCV in controls for five sample time
points (4weeks in between) with three sample time points (also
4 weeks in between; Supplementary material online, Figure S2 and
Table S2). Collectively, the indices were numerically in the same
order of magnitude, and statistical differences between healthy
controls and chronic HF patients were comparable regardless of
the sample regimen. However, for some markers, there were
differences, especially for hsTnT. We conclude, therefore, that
biological variation indices may fluctuate with the sample regimen,
and this should be addressed in studies such as ours. .
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. Biomarker values and gender differences
Tables S3 and S4 in the Supplementary material online display the
levels of all the biomarkers for the complete data set, stratified
by sex in both healthy subjects and chronic HF patients. In healthy
subjects, NT-proBNP (P< 0.001), PRC (P= 0.013), and creatinine
(P< 0.001) were significantly different between males and females.
In the HF cohort, we observed a comparable difference regarding
creatinine (P= 0.006). In addition, lower ST2 levels (P= 0.008)
and higher phosphate levels (P= 0.01) were observed in females
compared with males.
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Biological variation indices for all biomarkers in healthy subjects
Log normal
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CVa CVi CVg II RCV (%) RCV up RCV down. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Established biomarkers
NT-proBNP 3.3 25.1 54.0 0.5 70.7 107.0 −48.2
hsTnT 1.5 16.0 51.2 0.3 44.9 83.4 −27.0
Novel biomarkers
Galectin-3 3.2 8.1 21.0 0.4 24.6 28.5 −21.3
GDF-15 15.2 18.9 47.6 0.5 69.9 113.3 −43.1
ST2 2.9 10.5 30.4 0.4 31.9 40.9 −25.0
Renal/neurohormonal biomarkers
Creatinine 1.6 4.1 14.4 0.3 12.4 13.3 −11.5
Plasma renin concentration 2.3 30.1 41.6 0.7 83.8 154.1 −50.7
Aldosterone 6.2 36.6 34.7 1.1 104.2 199.6 −58.9
Phosphate 1.3 6.9 8.2 0.9 19.8 22.0 −17.6
PTH 1.1 16.7 39.8 0.4 46.3 63.5 −34.8
hsTnT (n= 5) 4.4 19.8 56.8 0.4 57.0 78.7 −41.7
Electrolytes
Calcium 1.5 1.7 3.2 0.7 6.6 5.0 −4.8
Sodium 0.7 1.9 2.3 1.6 5.9 4.8 −4.5
CVa, analytical coefficient of variation; CVg, interindividual coefficient of variation; CVi, intraindividual coefficient of variation; GDF-15, growth differentiation factor 15; hsTnT,
high-sensitivity troponin T; II, index of individuality; PTH, parathyroid hormone; RCV, reference change value; ST2, suppression of tumorigenicity 2.
Table 5 Biological variation indices for all biomarkers in chronic heart failure patients
Log normal
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CVa CVi CVg II RCV (%) RCV up RCV down. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Established biomarkers
NT-proBNP 3.3 21.8 116.3 0.2 61.7 104.9 −40.1
hsTnT 1.5 11.1 96.6 0.1 31.4 42.6 −22.1
Novel biomarkers
Galectin-3 3.2 8.1 21.2 0.4 25.0 30.2 −20.1
GDF-15 15.2 16.6 77.1 0.3 64.3 78.2 −38.3
ST2 2.9 15.0 36.9 0.4 42.9 62.7 −31.4
Renal/neurohormonal biomarkers
Creatinine 1.6 5.0 19.6 0.3 15.0 16.5 −13.3
Plasma renin concentration 2.3 32.6 222.2 0.1 90.8 180.6 −51.2
Aldosterone 6.2 27.7 91.1 0.3 80.2 139.3 −48.9
Phosphate 1.3 10.7 17.4 0.6 30.0 38.7 −24.3
PTH 1.1 22.5 49.2 0.5 62.4 93.0 −43.3
hsTnT (n= 49) 4.4 13.4 70.4 0.1 37.6 52.1 −28.3
Electrolytes
Calcium 1.5 1.6 3.3 0.7 6.3 5.4 −5.0
Sodium 0.7 0.8 1.3 0.9 3.1 2.7 −2.6
CVa, analytical coefficient of variation; CVg, interindividual coefficient of variation; CVi, intraindividual coefficient of variation; GDF-15, growth differentiation factor 15; hsTnT,
high-sensitivity troponin T; II, index of individuality; PTH, parathyroid hormone; RCV, reference change value; ST2, suppression of tumorigenicity 2.
Discussion
Although several biomarkers are incorporated in daily clinical care
of HF, and the use of several others may become more common
in the coming years, we have insufficient knowledge on biological
variation in patients suffering from HF. Such knowledge is critical .
..
..
..
..
..
..
..
.. to ascertain whether a given change in biomarker levels indicates
if a HF patient migrates from a stable phase to a vulnerable phase,
with higher risk for (acute) admission.
Our study provides the indices of biological variation in healthy
subjects and chronic HF patients. We did not limit our study
to a single biomarker but measured the biological variation of
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Scatter plot with regression line of the intraindividual coefficient of variation (CVi)i and the log-transformed biomarker level
(established and novel). hsTnT, high-sensitivity troponin T; GDF-15, growth differentiation factor 15; ST2, suppression of tumorigenicity 2.
multiple HF biomarkers which are (i) established; (ii) have great
potential; and (iii) are related to the renal/neurohormonal sys-
tem. Although the crude levels of the biomarkers are significantly
different between healthy subjects and stable HF patients, a compa-
rable biological variation was clearly observed. Even the CVi was
not influenced by individual levels of the biomarker itself. These
findings might be similar regarding other patient groups such as
patients with kidney disease or high blood pressure, although future
research needs to unravel this further.
Most studies regarding the biological variation of natriuretic
peptides have focused on healthy individuals,23,24 but recently
several studies addressed biological variation of HF biomarkers.
Bruins et al.17 focused on natriuretic peptides and demonstrated
in 43 HF patients that NT-proBNP had lower variation than BNP.
They observed an even higher RCV of NT-proBNP compared with
our study (98%). Schindler et al.18 demonstrated in 20 controls
and 59 HF patients the biological variation of galectin-3, BNP, and
troponin I. The CVi and RCV of galectin-3 were comparable with
those of our study and they concluded that galectin-3 could be a
useful asset in monitoring HF patients because of its low biological
variation indices. Since they measured BNP and troponin I, but
neither NT-proBNP nor hsTnT or any other marker, a direct
comparison with our data is not possible. Finally, Wu et al.16 inves-
tigated the biological variation of galectin-3 and ST2 in 12 healthy
subjects, sampling blood every 2 weeks for 8 weeks. In this study,
the RCV for ST2 and galectin-3 was 30% and 60%, respectively,
but we could not validate these RCVs. In our HF patients, we
demonstrated an RCV for galectin-3 of 25% (and of 25% in healthy
controls). This RCV for HF patients is almost identical to that
reported by Schindler et al. (27%),18 but these authors reported
an even lower RCV for galectin-3 in healthy controls (15%). Very
recently, Piper et al.25 demonstrated in 50 patients with chronic .
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.. HF that variability indices of ST2 are comparable with short- and
long-term sample intervals (from hours to 6 months). We report
an RCV of 32% in healthy controls, which is close to the RCV
reported by Wu et al.,16 whereas for HF patients the RCV was
43%, comparable with that of Piper et al.25 Solid insights in the
RCV of ST2 may be useful, as the use of serial ST2 samples has
been advocated to guide drug treatment.26
Further, this study also reports on biological variation of sev-
eral other neurohormonal and emerging biomarkers. The renin and
aldosterone hormones have been studied in HF patients and pro-
vide some prognostic information.27,28 We, however, herein show
that the biological variation is very wide and thus only substan-
tial changes (doubling or more) could be considered as relevant.
PTH is a marker of parathyroid function but, recently, there has
been strong interest in its potential role in HF development.29
We now report that RCV for PTH appears to be in the same
range as NT-proBNP. Markers of renal function such as creati-
nine are widely used and we show that CVi is low. There are
numerous studies that addressed the clinical utility of creatinine
and other markers of renal function.30 Finally, GDF-15 is an emerg-
ing biomarker of cardiovascular disease and HF.31,32 Our results
show that CVi and RCV are comparable with NT-proBNP, suggest-
ing that GDF-15 may vary considerably within and between indi-
viduals, and that only substantial variation hints towards relevant
changes.
The size and design of our study also allowed us to conduct
several subanalyses. We observed significantly lower NT-proBNP
levels in healthy male subjects compared with female subjects.
Costello-Boerrigter et al.33 stated that NT-proBNP levels in
healthy subjects are primarily affected by gender and age, and
that this should be considered when interpreting values. As in the
control group, only few females were present in the chronic HF
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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cohort, but they had significantly lower ST2 levels than males. This
was also observed in the Framingham Heart Study.34
From a clinical point of view, a pre-defined threshold is usually
observed when considering serial measurements of HF biomarkers
(does it rise above or below the threshold?). The assumption is
that this methodology would identify patients who are at high/low
risk or, when they go over the threshold, should be reclassified
into low/high risk (categorical). This approach neglects, at least to
some extent, the individual change within a subject. Clinicians could
make use of the RCVs derived from our study and other studies
in clinical practice, and this could help to initiate a more tailored
clinical approach.
Although some speculate that the interpretation of variation,
especially of natriuretic peptides, should only be based upon clinical
criteria,35 we argue that when a patient-specific threshold is passed,
this is a sign of either disease improvement or deterioration.
Clinically, there are numerous studies that reported the value of
serial biomarker measurements. For instance, serial measurements
of NT-proBNP,7 TnT,36 galectin-3,37 ST2,5 and GDF-1538 were
performed in the Valsartan Heart Failure Trial (Val-HeFT). In the
relative change analyses, the authors frequently used, amongst
other methodology, a cut-off of 15–30%, but rarely was a clear
rationale behind these decisions provided. Thus, it may be that
those groups with higher values are enriched with patients whose
values will continue to diminish. However, such cut-off values
may not serve individual patients optimally. Van der Velde et al.
demonstrated a similar prognostic value of changes in galectin-3
levels over time in the Coordinating study evaluating Outcomes
of Advising and Counseling in Heart Failure (COACH) study.6
Although changes over time of all these biomarkers were reported
to have prognostic value, clearly the biological variation profile
of these markers is very different, and it would have been logical
to study the changes keeping in mind the biomarker-specific
RCVs. In general, for biomarkers with high within-individual or
between-individual biological variation, it is less clear what a given
variation ‘reveals’. In the HABIT trial (Heart Failure assessment
with BNP in the Home)39 nearly 7000 BNP values were recorded
on a daily basis in 163 acute HF patients after discharge. It was
observed that ‘normal’ fluctuation within these patients is hard
to predict, and extremely variable BNP values were observed in
these more severe and recently unstable HF patients. We argue
that studies on variability should be conducted preferably during
stable periods, but it should also be considered that there may be
differences in variability between measurements performed hour
to hour, or week to week, or month to month. Even more difficult,
assessment of variability in acute HF patients is also a topic that has
not yet been explored in depth. Minor variations in NT-proBNP
and GDF-15 are difficult to interpret, and they might not be so use-
ful in monitoring individual patients. On the other hand, variations
in galectin-3, hsTnT, and ST2 are more likely to hint towards a true
change. A biomarker with less variation may seem to be inferior to
pick up changes in clinical status as compared with those biomark-
ers that have larger variation—at the expense of less accuracy due
to this larger variation. Therefore, the RCV should be placed into
perspective of the expected changes of the biomarker. If the range
of a biomarker is limited, a relatively low RCV could be more ..
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.. relevant than a larger one for a biomarker that has a much larger
range.
Strengths and weaknesses
This is the largest study addressing biological variation in
HF biomarkers including both healthy subjects and chronic
HF patients, testing a broad range of established, novel, and
renal/neurohormonal biomarkers. We also describe sex differ-
ences for all biomarkers and electrolytes in both healthy subjects
and HF patients. We report biological variation of the emerging
markers ST2 and GDF-15 for the first time. Owing to the study
design, we could only assess biological variation for a time period
of 6 weeks where we obtained three blood samples, and thus can-
not provide hourly or daily variation. Because of the observational
design of the HF study, we were not able to assess to what extent
the calculated RCV would be of prognostic value. Both studies
only included Caucasian subjects. Although we attempted to use
commonly available, widely used, commercial assays, we are aware
that some assays may have advantages over others.40–42
In addition, we studied by design a well-treated stable HF cohort.
Indeed, studying unstable patients is much more complex since
they may manifest disease-related changes in addition to biological
variation. Nonetheless, we would argue that our data provide a
reasonable baseline to us even with less stable patients.
Conclusion
We determined the biological variation of a broad spectrum of
well-established and novel biomarkers of HF in 28 healthy subjects
and 83 chronic HF patients. Indices of biological variation of this
large biomarker panel were comparable for both groups. We
confirm a high CVi and RCV of NT-proBNP and describe this
for GDF-15 as well, whereas other biomarkers showed lower
variation: ST2, hs-TnT, and galectin-3 (in descending order). A
demonstrated lower CVi and RCV renders biomarkers more
suitable for patient follow-up and biomarker targeted strategy
programmes, and such indices should be described in studies with
serial biomarker measurements.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
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